Is GeneDx Holdings Corp. overvalued or undervalued?

As of 29 July 2025, the valuation grade for GeneDx Holdings Corp. has moved from risky to attractive, indicating a more favorable outlook. Based on the available metrics, the company appears to be undervalued. The Price to Book Value stands at 7.99, while the EV to Sales ratio is 5.92, suggesting that the market may not fully recognize the company's potential relative to its assets and sales.
In comparison to its peer, Aveanna Healthcare Holdings, Inc., which has a P/E ratio of 31.16 and an EV to EBITDA of 12.45, GeneDx's valuation ratios highlight a significant disparity, particularly given its EV to EBITDA of 188.80. This suggests that while GeneDx is currently seen as attractive, its high valuation ratios compared to peers may indicate overvaluation in the long term. Notably, GeneDx has outperformed the S&P 500 significantly, with a year-to-date return of 70.06% compared to the index's 12.22%, reinforcing the notion of its growth potential.